Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20910162 | 1.00 | KDM4E (0.34) | KDM4EALDH1A1DDB1CRBNKDM5A | |
| SCHEMBL22494517 | 1.00 | KDM4E (0.34) | KDM4EALDH1A1DDB1CRBNKDM5A | |
| SCHEMBL20437003 | 0.81 | CRBN (0.47) | ALDH1A1DDB1CRBN | |
| SCHEMBL23168734 | 0.81 | BTK (0.36) | KDM4EALDH1A1DDB1CRBNKDM5A | |
| SCHEMBL22060808 | 0.75 | SRC (0.35) | KDM5A | |
| SCHEMBL17040075 | 0.71 | BTK (0.41) | KDM4EALDH1A1KDM5ABTK | |
| SCHEMBL20899095 | 0.70 | KDM4E (0.36) | KDM4EALDH1A1LRRK2 | |
| SCHEMBL20519845 | 0.70 | MAP4K1 (0.37) | KDM5A | |
| SCHEMBL16899742 | 0.70 | MPO (0.38) | KDM4EDDB1CRBNKDM5A | |
| SCHEMBL1428386 | 0.69 | CHRNB2 (0.48) | ALDH1A1DDB1CRBNKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | SYROS PHARMACEUTICALS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | SYROS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147431-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | KDM4E 727/4885ALDH1A1 3763/4885DDB1 1407/4885 |
| US-20200317676-A1 | PYRROLOTRIAZINE COMPOUNDS AND METHODS OF INHIBITING TAM KINASES | PLK2, MAP3K5, CAMKK2 | KDM4E 727/4885ALDH1A1 3763/4885DDB1 1407/4885 |
| US-11040981-B2 | Pyrrolotriazine compounds and methods of inhibiting TAM kinases | PLK2, MAP3K5, CAMKK2 | KDM4E 727/4885ALDH1A1 3763/4885DDB1 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.